CytomX Therapeutics, Inc. — Director's Dealing 2016

Sep 28, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CytomX Therapeutics, Inc. (CTMX)
CIK: 0001501989
Period of Report: 2016-09-26

Reporting Person: McCarthy Sean A. (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-09-26	Stock Option (Right to Buy)	$0.9450	A	48379	Acquired	2023-02-25	Common Stock (48379)	Direct
2016-09-26	Stock Option (Right to Buy)	$1.5749	A	122424	Acquired	2025-02-08	Common Stock (122424)	Direct

Footnotes

F1: On February 26, 2013, the Reporting Person was granted an option to purchase 96,758 shares of Common Stock, as adjusted for the 1-for-62.997 reverse stock split effected prior to the Issuer's initial public offering, to vest in two equal tranches upon achievement of certain performance-based milestones (the "Performance Option"). 50% of the Performance Option previously vested upon achievement of the first performance milestone. On September 26, 2016, the second performance milestone was achieved resulting in vesting of the remaining 50% of the Performance Option.

F2: On February 9, 2015, the Reporting Person was granted an option to purchase 122,424 shares of Common Stock, as adjusted for the 1-for-62.997 reverse stock split effected prior to the Issuer's initial public offering, to vest in full upon achievement of a certain performance-based milestone (the "Performance Option"). On September 26, 2016, the performance milestone was achieved resulting in 100% of the Performance Option vesting.